|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Coburn NG: Lymph nodes and gastric cancer.
J Surg Oncol. 99:199–206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tang H, Liu X, Wang Z, et al: Interaction
of hsa-miR-381 and glioma suppressor LRRC4 is involved in glioma
growth. Brain Res. 1390:21–32. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cheng CJ and Slack FJ: The duality of
oncomiR addiction in the maintenance and treatment of cancer.
Cancer J. 18:232–237. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tang H, Deng M, Tang Y, et al: miR-200b
and miR-200c as prognostic factors and mediators of gastric cancer
cell progression. Clin Cancer Res. 19:5602–5612. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zheng B, Liang L, Wang C, et al:
MicroRNA-148a suppresses tumor cell invasion and metastasis by
downregulating ROCK1 in gastric cancer. Clin Cancer Res.
17:7574–7583. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu D, Xia P, Diao D, et al: MiRNA-429
suppresses the growth of gastric cancer cells in vitro. J Biomed
Res. 26:389–393. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
He XP, Shao Y, Li XL, et al:
Downregulation of miR-101 in gastric cancer correlates with
cyclooxygenase-2 overexpression and tumor growth. FEBS J.
279:4201–4212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang L, Liu X, Jin H, et al: miR-206
inhibits gastric cancer proliferation in part by repressing
cyclinD2. Cancer Lett. 332:94–101. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Qin S, Ai F, Ji WF, Rao W, Zhang HC and
Yao WJ: miR-19a promotes cell growth and tumorigenesis through
targeting SOCS1 in gastric cancer. Asian Pac J Cancer Prev.
14:835–840. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang M, Li C, Yu B, et al: Overexpressed
miR-301a promotes cell proliferation and invasion by targeting
RUNX3 in gastric cancer. J Gastroenterol. 48:1023–1033. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu W, Takanashi M, Borjigin N, et al:
MicroRNA-18a modulates STAT3 activity through negative regulation
of PIAS3 during gastric adenocarcinogenesis. Br J Cancer.
108:653–661. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang ZX, Lu CY, Yang YL, Dou KF and Tao
KS: MicroRNA- 125b expression in gastric adenocarcinoma and its
effect on the proliferation of gastric cancer cells. Mol Med Rep.
7:229–232. 2013.PubMed/NCBI
|
|
14
|
Zhi Q, Guo X, Guo L, et al: Oncogenic
miR-544 is an important molecular target in gastric cancer.
Anticancer Agents Med Chem. 13:270–275. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guo JX, Tao QS, Lou PR, Chen XC, Chen J
and Yuan GB: miR-181b as a potential molecular target for
anticancer therapy of gastric neoplasms. Asian Pac J Cancer Prev.
13:2263–2267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tang H, Kong Y, Guo J, et al: Diallyl
disulfide suppresses proliferation and induces apoptosis in human
gastric cancer through Wnt-1 signaling pathway by up-regulation of
miR-200b and miR-22. Cancer Lett. 340:72–81. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo MM, Hu LH, Wang YQ, et al: miR-22 is
down-regulated in gastric cancer, and its overexpression inhibits
cell migration and invasion via targeting transcription factor Sp1.
Med Oncol. 30:5422013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li B, Song Y, Liu TJ, et al: miRNA-22
suppresses colon cancer cell migration and invasion by inhibiting
the expression of T-cell lymphoma invasion and metastasis 1 and
matrix metalloproteinases 2 and 9. Oncol Rep. 29:1932–1938.
2013.PubMed/NCBI
|
|
19
|
Ling B, Wang GX, Long G, Qiu JH and Hu ZL:
Tumor suppressor miR-22 suppresses lung cancer cell progression
through post-transcriptional regulation of ErbB3. J Cancer Res Clin
Oncol. 138:1355–1361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xiong J, Yu D, Wei N, et al: An estrogen
receptor alpha suppressor, microRNA-22, is downregulated in
estrogen receptor alpha-positive human breast cancer cell lines and
clinical samples. FEBS J. 277:1684–1694. 2010. View Article : Google Scholar
|
|
21
|
Wang W, Li F, Zhang Y, Tu Y, Yang Q and
Gao X: Reduced expression of miR-22 in gastric cancer is related to
clinicopathologic characteristics or patient prognosis. Diagn
Pathol. 8:1022013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Song SJ, Ito K, Ala U, et al: The
oncogenic microRNA miR-22 targets the TET2 tumor suppressor to
promote hematopoietic stem cell self-renewal and transformation.
Cell Stem Cell. 13:87–101. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kang DC, Su ZZ, Sarkar D, Emdad L, Volsky
DJ and Fisher PB: Cloning and characterization of HIV-1-inducible
astrocyte elevated gene-1, AEG-1. Gene. 353:8–15. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu L, Wu J, Ying Z, et al: Astrocyte
elevated gene-1 upregulates matrix metalloproteinase-9 and induces
human glioma invasion. Cancer Res. 70:3750–3759. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ahn S, Hyeon J and Park CK: Metadherin is
a prognostic predictor of hepatocellular carcinoma after curative
hepatectomy. Gut Liver. 7:206–212. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang N, Du X, Zang L, et al: Prognostic
impact of Metadherin-SND1 interaction in colon cancer. Mol Biol
Rep. 39:10497–10504. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tokunaga E, Nakashima Y, Yamashita N, et
al: Overexpression of metadherin/MTDH is associated with an
aggressive phenotype and a poor prognosis in invasive breast
cancer. Breast Cancer. 21:341–349. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou J, Li J, Wang Z, Yin C and Zhang W:
Metadherin is a novel prognostic marker for bladder cancer
progression and overall patient survival. Asia Pac J Clin Oncol.
8:e42–e48. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Meng X, Brachova P, Yang S, et al:
Knockdown of MTDH sensitizes endometrial cancer cells to cell death
induction by death receptor ligand TRAIL and HDAC inhibitor LBH589
co-treatment. PLoS One. 6:e209202011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ge X, Lv X, Feng L, et al: Metadherin
contributes to the pathogenesis of diffuse large B-cell lymphoma.
PLoS One. 7:e394492012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang J, Zhang Y, Liu S, et al: Metadherin
confers chemoresistance of cervical cancer cells by inducing
autophagy and activating ERK/NF-κB pathway. Tumour Biol.
34:2433–2440. 2013.PubMed/NCBI
|
|
32
|
Hu G, Wei Y and Kang Y: The multifaceted
role of MTDH/AEG-1 in cancer progression. Clin Cancer Res.
15:5615–5620. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li X, Kong X, Huo Q, et al: Metadherin
enhances the invasiveness of breast cancer cells by inducing
epithelial to mesenchymal transition. Cancer Sci. 102:1151–1157.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhu K, Dai Z, Pan Q, et al: Metadherin
promotes hepatocellular carcinoma metastasis through induction of
epithelial-mesenchymal transition. Clin Cancer Res. 17:7294–7302.
2011. View Article : Google Scholar
|
